VOYAGER THERAPEUTICS INC (VYGR)
Health Care · Genetic medicine / Gene therapy · NASDAQ
Voyager Therapeutics is a gene therapy company utilizing its proprietary TRACER AAV platform to develop intravenous, brain-penetrant treatments for severe neurological diseases.
What VOYAGER THERAPEUTICS INC does
Voyager Therapeutics is a biotechnology company focused on developing gene therapies and other modalities for neurological diseases. Its primary asset is the TRACER AAV capsid discovery platform, which is designed to enable high brain penetration for genetic medicines delivered intravenously. The company's pipeline includes both wholly-owned programs for Alzheimer's disease and collaborative programs for conditions such as Friedreich’s ataxia, Parkinson’s disease, and ALS.
Recent developments
Voyager expects to initiate dosing for its VY1706 gene therapy in early Alzheimer's patients in Q4 2026 following FDA IND clearance. Additionally, the company anticipates receiving tau PET imaging data for its VY7523 anti-tau antibody in Q4 2026. Financial guidance indicates that current cash, equivalents, and reimbursements are sufficient to fund operations into 2028.
From VOYAGER THERAPEUTICS INC's filing of 2026-08-06.
Themes: gene therapy, CNS / neurological diseases, Alzheimer's disease drug development, blood-brain barrier delivery, AAV vector technology
Fundamentals
- Price$2.37 as of 2026-10-08 close
- Market cap$146M as of 2026-07-30 (share count; price 2026-10-08)
- 1-year return-55.1% 2025-10-08 close $5.28 → 2026-10-08 close $2.37
- P/En/a negative earnings
- Net margin-296.5% FY2025, SEC XBRL
- ROE-61.1% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-19.1% as of 2026-09-02
- Revenue CAGR (3y)-0.4% SEC XBRL
- Beta1.41 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How VYGR compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VOYAGER THERAPEUTICS INC looks technically
VOYAGER THERAPEUTICS INC (VYGR) is trading 34.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 137 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 22, in oversold territory (below 30). It just made a new 20-day low, breaking below its recent trading range. It is 1.7% above its 52-week low (its lowest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 34.7% below its 200-day average, the long-term trend line — a long-term downtrend | -34.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.10 | $3.10 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.63 | $3.63 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 137 trading days ago — a "death cross", a bearish long-term signal | 137 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with sellers in control | 43.0 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 22, in oversold territory (below 30) | 22.2 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($2.33 to $3.17) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 4.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.55 | $5.55 |
|---|---|---|
| From the 52-week high | it is 57.3% below its 52-week high (its highest price of the past year) | -57.3% |
| Above the 52-week low | it is 1.7% above its 52-week low (its lowest price of the past year) | +1.7% |
| Below the 52-week high | it is 57.3% below its highest point of the past year | 57.3% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $31.91 (set on 2018-03-05) | $31.91 |
| Given back of the 52-week move | over the past year its closes ranged ($2.37 to $5.33), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.20 to $4.29. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 92.6% below its all-time high | -92.6% |
| Nearest price level | it is trading 24.5% below a resistance level at $2.95 — a price it turned at twice since 2026-07-23, most recently on 2026-08-03. Since 2024-10-08 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +24.5% |
| All-time low | its lowest closing price on record is $2.33 (set on 2026-10-08) | $2.33 |
| Above the all-time low | it is 1.7% above its all-time low | +1.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1447 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1447 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.26 and $3.36 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.26 – $2.81 – $3.36 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 8.7 daily ranges below its 200-day average price (34.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.8% |
|---|---|---|
| Gap filled | a 3.0% gap up opened on 2026-08-03 has been "filled" 47 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 47 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 31.3 percentage points (the stock lost 30.3% while the market gained 1.0%) | -31.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 40.3 percentage points (the stock lost 36.5% while the market gained 3.8%) | -40.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 57.8 percentage points (the stock lost 40.3% while the market gained 17.5%) | -57.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 70.1 percentage points (the stock lost 55.1% while the market gained 15.0%) | -70.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 29% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.5% of the share price. | -28.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 35% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.67 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -35.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 21% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.00 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -21.0% |
Price levels it has turned at before
VYGR last closed at $2.37 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.95 | Resistance | 24.5% above the last close | turned there twice · 2026-07-23 to 2026-08-03 |
| $3.27 | Resistance | 38.0% above the last close | turned there four times · 2025-08-21 to 2026-07-27 |
| $3.35 | Resistance | 41.1% above the last close | turned there twice · 2026-05-19 to 2026-08-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · Near the all-time low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$14.89 range $8.00 – $25.00; median $12.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VYGR
- Consensus EPS estimate-$0.4181 next reporting period, as of 2026-10-07
- Estimate change, 30 days$0.00 from -$0.4181, on 2026-09-02, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of net losses and dependence on collaborative partnerships for revenue.","Clinical trial failures or delays in obtaining regulatory approvals for its genetic medicine pipeline.","Technical risks inherent in developing AAV capsids and overcoming the blood-brain barrier."]
What changed in the latest 10-Q
AI-assisted comparison of VYGR's 10-Q filed 2026-05-07 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for fiscal year ended December 31, 2025, filed March 9, 2026 (vs. December 31, 2024, filed March 11, 2025 in older filing)
- Newer filing states VY1706 completed GLP toxicology in Q1 2026 and had Type C communication with FDA in Q1 2026
- Newer filing states anticipation of IND application completion in Q2 2026 and clinical trial initiation in second half of 2026 for VY1706
- Newer filing states VY7523 MAD enrollment completed in Q4 2025 and expects initial tau PET imaging efficacy data in second half of 2026
- Newer filing states NBIB-'223 received orphan drug designation in May 2026 for FA treatment
- Newer filing states Neurocrine intends to initiate clinical trial with NBIB-'223 for FA in second half of 2026
- Newer filing states GLP toxicology studies for NBIB-'223 are now complete
- Newer filing specifies profit/loss allocation for FA Program (60% Neurocrine, 40% Voyager) and GBA1 Program (50% each) in U.S.
- Newer filing references Transition Bio collaboration as research stage and mentions option for exclusive worldwide license
- Newer filing states partnership milestone potential of $6.8 billion with $2.4 billion in development milestones (same figures as older)
- Removed:
- Older filing mentioned APOE gene therapy program designed to knock down APOE in APOE4 carriers
- Older filing mentioned deprioritization of SOD1-ALS gene therapy and anti-Aβ antibody gene therapy programs in Q3 2025
- Older filing stated Neurocrine expected to provide IND filing timeline updates by end of 2025
- Older filing described Transition Bio collaboration approach targeting biomolecular condensates for TDP-43 mislocalization correction
- Older filing stated Transition Bio collaboration included single-digit million-dollar upfront payment and up to $500.0 million in milestone payments
- Older filing mentioned tiered royalties for Transition Bio on net sales
- Older filing referenced capsid licenses to Novartis for three undisclosed CNS targets with termination of two in Q1 2026
- Older filing mentioned fourth development candidate in gen[esis] (text cut off) with Neurocrine preclinical toxicology study
- Reworded:
- Newer filing lists collaborators as 'Alexion, AstraZeneca Rare Disease, or Alexion; Novartis Pharma AG, or Novartis; Neurocrine Biosciences, Inc., or Neurocrine; and Transition Bio, Inc., or Transition Bio' vs. older omitting Transition Bio from initial list
- Newer filing lists tau programs as 'VY1706, a tau silencing gene therapy for AD, and VY7523, an anti-tau antibody for AD' vs. older listing 'VY7523...and VY1706' (reversed order)
- Newer filing describes Parkinson's disease as 'or PD' vs. older without abbreviation in initial overview
- Newer filing states VY7523 'Enrollment in this MAD clinical trial was completed in the fourth quarter of 2025' vs. older 'We believe this trial has the potential to generate initial data in the second half of 2026'
- Newer filing states VY1706 'We completed investigational new drug-enabling good laboratory practices...toxicology in the first quarter of 2026' vs. older 'We anticipate the submission of an IND application and initiation of a clinical trial for the VY1706 program in 2026'
- Newer filing shortens Transition Bio description to focus on research stage collaboration vs. older detailed explanation of biomolecular condensates approach
- Newer filing refers to 'FA Program' and 'GBA1 Program' with profit allocation details vs. older using 'which we refer to as' phrasing without allocation specifics
- Notes:
- Text of newer filing is truncated at 'multipl' suggesting incomplete excerpt
- Text of older filing is truncated at 'gen' suggesting incomplete excerpt
- Comparison based on available portions of MD&A sections
Risk Factors
- Reworded:
- Newer filing (2026-05-07) reordered phrase from 'we may enter into or make' to 'we may make or enter into' regarding future acquisitions, mergers, etc.
- Newer filing (2026-05-07) added 'not' in trademark section: 'may appear' vs older filing (2025-11-10) 'may appear without the ® or TM symbols' - content is substantively the same but newer version includes fuller text in provided excerpt
- Notes:
- The two filings compare Risk Factors introductory language and forward-looking statement disclaimers. The substantive Risk Factors section itself (Item 1A detailed content) was not provided in either excerpt, limiting assessment to the preamble text.
- Comparison is of Risk Factors section preamble/boilerplate language; actual risk factor disclosures may differ but were not included in source texts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2026-04-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VYGR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VYGR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,700,523
- Reported value $30,451,832
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about VYGR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
VYGR had 3,655,802 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
VYGR had 5.93% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.61 days to cover at the same settlement.
- Reported short interest (shares) 3,655,802
- Short interest (% of shares outstanding) 5.93%
- Prior settlement (shares) 3,785,882
- Reported change -3.44%
- Days to cover (reported) 8.61
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Neurocrine Biosciences (NBIX)
- Novartis (NVS)
- AstraZeneca (AZN)
- Biogen (BIIB)
- Eli Lilly (LLY)
- Regenxbio (RGNX)
- Sarepta Therapeutics (SRPT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VYGR vs…
VOYAGER THERAPEUTICS INC is found in…
Frequently asked questions
What does VOYAGER THERAPEUTICS INC (VYGR) do?
Voyager Therapeutics is a biotechnology company focused on developing gene therapies and other modalities for neurological diseases. Its primary asset is the TRACER AAV capsid discovery platform, which is designed to enable high brain penetration for genetic medicines delivered intravenously. The company's pipeline includes both wholly-owned programs for Alzheimer's disease and collaborative programs for conditions such as Friedreich’s ataxia, Parkinson’s disease, and ALS.
What sector is VOYAGER THERAPEUTICS INC (VYGR) in?
VOYAGER THERAPEUTICS INC (VYGR) is classified in the Health Care sector. Its industry is Genetic medicine / Gene therapy. It trades on NASDAQ.
Who are VOYAGER THERAPEUTICS INC's (VYGR) competitors?
Notable peers of VOYAGER THERAPEUTICS INC (VYGR) include Neurocrine Biosciences, Novartis, AstraZeneca, Biogen and Eli Lilly. This peer set is informational only — not financial advice.
Is VOYAGER THERAPEUTICS INC (VYGR) overbought or oversold right now?
VOYAGER THERAPEUTICS INC (VYGR) is currently in oversold territory (its 14-day RSI is 22, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VYGR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.